Patents Assigned to Bioscience, Inc.
  • Patent number: 12252513
    Abstract: Provided herein are novel thermostable phycobiliproteins. These proteins may be stabilized by the introduction of disulfide bonds which stabilize the protein. Modified cells expressing these thermostable phycobiliproteins and methods of making them are also provided.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 18, 2025
    Assignee: Lumen Bioscience, Inc.
    Inventors: James Roberts, Ryo Takeuchi, Nhi Khuong, Barry L Stoddard, Rolf Kuestner
  • Publication number: 20250082735
    Abstract: The present invention provides a method of treating a nucleotide repeat expansion disorder comprising delivering a pair of engineered nucleases, or genes encoding engineered nucleases, to the cells of a patient such that the two nucleases excise the nucleotide repeat responsible for the disease permanently from the genome. The invention provides a general method for treating nucleotide repeat expansion disorders and engineered nucleases suitable for practicing the method. The invention further provides vectors and techniques for delivering engineered nucleases to patient cells.
    Type: Application
    Filed: July 11, 2024
    Publication date: March 13, 2025
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Victor Bartsevich, Derek Jantz
  • Publication number: 20250084372
    Abstract: Provided herein are methods of generating gonadal cell populations such as ovarian somatic cells from pluripotent stem cells. Also included are gonadal cell populations, as well as intermediate cell populations generated therein.
    Type: Application
    Filed: November 1, 2021
    Publication date: March 13, 2025
    Applicant: Conception Biosciences, Inc.
    Inventors: Rhishikesh BARGAJE, Karmen Seres, Pablo Hurtado-Gonzalez, Alyssa Miller
  • Patent number: 12246063
    Abstract: Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: March 11, 2025
    Assignee: Trellis Bioscience, Inc.
    Inventors: Milton J. Friedman, Lawrence M. Kauvar
  • Patent number: 12247193
    Abstract: Aspects of the present invention relate to a networked cell culture incubator and to methods for operating such an incubator. In one aspect, the cell culture incubator includes a network interface for communicating with a source of parameter data utilized successfully by other incubators. The incubator receives appropriate parameter data and conducts the incubation process as prescribed by the parameter data so as to provide an improved environment for cell culture growth. The incubator may share its own parameter data with the data source for use by other incubators. The incubator and data source may share other forms of data as well.
    Type: Grant
    Filed: January 3, 2024
    Date of Patent: March 11, 2025
    Assignee: Thrive Bioscience, Inc.
    Inventor: Howard Cannon
  • Publication number: 20250073503
    Abstract: Provided herein are wearable harnesses for securing and positioning an ultrasound device on a subject. The wearable harnesses can be used to position an ultrasound transducer to a human body. The wearable harnesses may include two adjustable shoulder straps, an adjustable waist strap, a pocket for holding a power pack, and a pocket for holding the transducer. For example, the pocket for holding the transducer may be positioned over the subject's spleen such that the ultrasound transducer may be positioned over the subject's spleen. Provided herein is also a treatment unit to be used to the wearable harness, that includes an ultrasound transducer; and a mechanical lens comprising a plurality of concentric rings and configured to adjust ultrasonic waves emitted by the ultrasound transducer.
    Type: Application
    Filed: January 12, 2023
    Publication date: March 6, 2025
    Applicant: INIA Biosciences, Inc.
    Inventors: Dragana SAVIC, Shen NING
  • Patent number: 12240879
    Abstract: Provided herein are a fusion protein comprising an interleukin-22 domain and an albumin binding domain, and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory disease.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: March 4, 2025
    Assignee: Anwita Biosciences, Inc.
    Inventors: Ziyang Zhong, Fan Ye, Jianing Huang, Matthew Siegel, Ji Wang
  • Patent number: 12240848
    Abstract: This invention provides rho-associated protein kinase (ROCK) inhibiting compounds for therapeutic applications as described further herein.
    Type: Grant
    Filed: March 19, 2024
    Date of Patent: March 4, 2025
    Assignee: Avicenna Biosciences, Inc.
    Inventor: Thomas Maxwell Kaiser
  • Publication number: 20250066477
    Abstract: Provided herein are VHH-containing polypeptides that bind ?? T-cells. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: January 4, 2023
    Publication date: February 27, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Kaitlyn N. Robinson, Andrew M. Eckles, John C. Timmer, Brendan P. Eckelman
  • Publication number: 20250066756
    Abstract: Provided are various embodiments relating to variant asparaginase polypeptides with enhanced stability, pharmacodynamics, and/or reduced immunogenicity. The variant asparaginase polypeptides may be used as therapeutics in mammals, including human, canines, felines, and equines.
    Type: Application
    Filed: August 23, 2024
    Publication date: February 27, 2025
    Applicant: Kindred Biosciences, Inc.
    Inventors: Hangjun Zhan, Lam Nguyen, Richard Chin, Shyr Jiann Li
  • Publication number: 20250066836
    Abstract: Provided are a method for analyzing the methylation status of at least one target sequence in a sample including providing a sample comprising DNA, wherein the DNA comprises at least one target sequence; contacting the sample with at least one methyltransferase that methylates non-cytosine nucleotides; and assaying the sample for the methylation status of one or more cytosine nucleotides in the at least one target sequence, and other related methods.
    Type: Application
    Filed: December 22, 2022
    Publication date: February 27, 2025
    Applicant: APR Biosciences Inc.
    Inventors: Wadiha Freije, Igor Brikun
  • Publication number: 20250064986
    Abstract: A method for expressing and delivering a polynucleotide encoding a protein of interest is provided herein. Specifically, the protein of interest can be a nuclease associated with a gene-editing system with increased half-life of the mRNA encoding an engineered nuclease, such that the protein level and the gene editing efficiency of the engineered nuclease is increased. In particular, the mRNA comprises a specific combination of 5? UTR sequence, Kozak sequence, and 3? UTR sequence. Further provided herein are pharmaceutical compositions comprising the polynucleotides, and methods of modifying the genome of a eukaryotic cells using the polynucleotides disclosed herein.
    Type: Application
    Filed: January 6, 2023
    Publication date: February 27, 2025
    Applicant: Precision BioSciences, Inc.
    Inventors: Jason Richard Harris, Armin Hekele
  • Patent number: 12235215
    Abstract: Methods include applying a first stain composition comprising a fluorescent counterstain to a biological sample, measuring information corresponding to one or more stains of the first stain composition, removing the fluorescent counterstain from the biological sample, applying a second stain composition to the biological sample, measuring information corresponding to one or more stains of the second stain composition in the biological sample, where the one or more stains include a fluorescent label, and generating a first image of the biological sample, where the first image corresponds to a pattern of simulated hematoxylin staining in the biological sample.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: February 25, 2025
    Assignee: Akoya Biosciences, Inc.
    Inventor: Michael McLane
  • Patent number: 12234216
    Abstract: Described herein are isotopically enriched analogs of methylone (e.g., deuterated analogs of methylone (e.g., (S)-methylone and (R)-methylone) with improved characteristics. Also described herein are salts (such as hydrochloride salt) and solid forms (e.g., crystalline forms) of methylone. Also described herein are stereoisomers (e.g., enantiomers) of methylone. The present disclosure also provides methods of making and methods of use of the methylone or methylone analogs and solid forms of 3,4-methylenedioxy-N-ethylcathinone hydrochloride described herein to treat brain and neurological disorders such as depression.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: February 25, 2025
    Assignee: Terran Biosciences Inc.
    Inventors: Samuel Clark, Matthew Duncton
  • Patent number: 12233115
    Abstract: The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.
    Type: Grant
    Filed: September 14, 2023
    Date of Patent: February 25, 2025
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Daniel B. Hall, Rachel Covitz, Garry Musso, Caroline Hill, Ahmet Vakkasoglu, Poul Strange, Tilmann M. Brotz
  • Patent number: 12234297
    Abstract: Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: February 25, 2025
    Assignees: Phylaxis Bioscience, LLC, Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Andrew M. Eckles, Brendan P. Eckelman, Tony Dung-Ling Yao
  • Patent number: 12234224
    Abstract: Pyrimidine and Pyridine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic metabolic and certain neurological disorders.
    Type: Grant
    Filed: December 6, 2023
    Date of Patent: February 25, 2025
    Assignee: EPIGEN Biosciences, Inc.
    Inventors: Graham Beaton, Fabio Tucci, Satheesh Ravula, Suk Joong Lee, Chandravadan Shah
  • Patent number: 12234505
    Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: February 25, 2025
    Assignee: Prognosys Biosciences, Inc.
    Inventor: Mark S. Chee
  • Publication number: 20250059279
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: August 2, 2024
    Publication date: February 20, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Patent number: 12226438
    Abstract: A method for a therapeutic compound from a plurality of birth tissues for the treatment of at least breathing and inflammation ailments. The method includes receiving a plurality of birth tissues from a mammalian donner. Each received birth tissue is processes to provide a refined material. This refined material is evaluated to determine at least a concentrate of at least one constituent. Portions of the processed birth tissues are then mixed to provide an initial blend of materials having a predetermined ration of the constituents to provide the therapeutic compound.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: February 18, 2025
    Assignee: Hilltop BioSciences, Inc.
    Inventors: Terrell Suddarth, Amanda Drobnis, Bruce Werber, David Dutton